Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637086 | 0.85 | TSHR (0.41) | TSHRKDM4ECA1CA2LMNA | |
| SCHEMBL19437188 | 0.80 | MPO (0.39) | MPOBCAT1TSHRTRPV4TAAR1 | |
| SCHEMBL22904169 | 0.80 | MPO (0.39) | MPOBCAT1TSHRTRPV4TAAR1 | |
| SCHEMBL12507402 | 0.80 | MPO (0.39) | MPOBCAT1TSHRTRPV4TAAR1 | |
| SCHEMBL17185834 | 0.80 | MPO (0.39) | MPOBCAT1TSHRTRPV4TAAR1 | |
| Acetonitrile SCHEMBL16963780 | 0.79 | KDM4E (0.38) | TSHRTAAR1POLBCUL4AKDM4E | |
| SCHEMBL121801 | 0.78 | TAAR1 (0.43) | TSHRTAAR1POLBTDP1KDM4E | |
| SCHEMBL30568075 | 0.78 | DYRK1A (0.42) | TSHRKDM4ECA1CA2LMNA | |
| SCHEMBL2780319 | 0.78 | DYRK1A (0.42) | TSHRKDM4ECA1CA2LMNA | |
| SCHEMBL3053661 | 0.78 | TSHR (0.35) | TSHRMAPTKDM4ECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-06 | — | — | US | disclosed |
| EP-4200301-B1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4219463-B1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-114981265-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010107435-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | EISAI CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20060100199-A1 | Novel condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060063787-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | MYT1, AQP4, AQP1 | MPO 581/4885BCAT1 3377/4885TSHR 1662/4885 |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | MPO 3804/4885BCAT1 2035/4885TSHR 2940/4885 |
| US-12415785-B2 | Compound modulators of sting | STING1, IRF3, MAVS | MPO 1397/4885BCAT1 4312/4885TSHR 4301/4885 |
| US-20060100199-A1 | Novel condensed imidazole derivatives | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 | MPO 1320/4885BCAT1 1617/4885TSHR 1753/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | MPO 317/4885BCAT1 1415/4885TSHR 1389/4885 |
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | MPO 1750/4885BCAT1 1136/4885TSHR 936/4885 |
| US-20060063787-A1 | Condensed imidazole derivatives | DPP4, HDAC1, DPP7 | MPO 715/4885BCAT1 1196/4885TSHR 1385/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | MPO 715/4885BCAT1 1196/4885TSHR 1385/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | MPO 708/4885BCAT1 3161/4885TSHR 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.